March 3 (Reuters) - Neuren Pharmaceuticals NEU.AX :
* ACADIA PHARMACEUTICALS AND NEUREN PHARMACEUTICALS ANNOUNCE RARE PEDIATRIC DISEASE DESIGNATION FOR TROFINETIDE FOR THE TREATMENT OF RETT SYNDROME
* NEUREN PHARMACEUTICALS - RESULTS FROM PHASE 3 LAVENDER STUDY EXPECTED IN 2021